Biologics License Application

A formal request submitted to the FDA for permission to introduce and market a biologic product into interstate commerce.

A Biologics License Application (BLA) is a comprehensive regulatory submission sent to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a biologic product in interstate commerce. Unlike traditional small-molecule drugs, which are chemically synthesized and approved via a New Drug Application (NDA), biologics are complex medicines derived from living sources such as cells, tissues, or microorganisms. Examples include vaccines, gene therapies, and monoclonal antibodies. The BLA contains exhaustive data demonstrating that the product is safe, pure, and potent. This includes detailed information on the manufacturing process, chemistry, pharmacology, clinical trial results, and the facilities where the biologic will be produced. The FDA reviews this data and inspects the manufacturing facilities to ensure they meet strict quality standards before granting approval. For biotechnology investors, the BLA process represents a series of critical binary events. The first major milestone is the FDA's acceptance of the BLA for filing, which confirms the submission is complete enough to undergo a full review. The final FDA decision on the BLA is the ultimate catalyst, as approval allows a development-stage biotech company to transition into a commercial-stage business and begin generating product revenue. Conversely, a rejection or a request for additional clinical trials can severely damage a company's stock price.

Biotech Company A submits a BLA for its new monoclonal antibody. The FDA accepts the filing and sets a PDUFA target action date. On that date, the FDA approves the BLA, allowing Company A to launch the drug commercially. Analysts project this approval will transition the company from $0 in product sales to an estimated $150 million in first-year revenue.